The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study

PURPOSE: Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell lung cancer (ES-SCLC) in some clinical studies. This research aimed to explore the real-world efficacy and safety o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Hao-Ran, Jiang, Ai-Min, Gao, Huan, Liu, Na, Zheng, Xiao-Qiang, Fu, Xiao, Zhang, Rui, Ruan, Zhi-Ping, Tian, Tao, Liang, Xuan, Yao, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356751/
https://www.ncbi.nlm.nih.gov/pubmed/35942069
http://dx.doi.org/10.2147/CMAR.S364125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356751/
https://www.ncbi.nlm.nih.gov/pubmed/35942069
http://dx.doi.org/10.2147/CMAR.S364125

Ejemplares similares